Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326393 | 0.90 | FBP1 (0.47) | FBP1POLBMAPTAKR1C3AKR1C2 | |
| SCHEMBL2324511 | 0.90 | MAPT (0.54) | FBP1MAPTAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL7719673 | 0.88 | FBP1 (0.48) | FBP1POLBMAPTTHRBAKR1C3 | |
| SCHEMBL2329245 | 0.87 | ALDH1A1 (0.46) | POLBMAPTAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL2213212 | 0.87 | MAPT (0.45) | FBP1MAPTAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL2323214 | 0.86 | HDAC1 (0.47) | FBP1MAPTAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL2323733 | 0.86 | MAPT (0.55) | FBP1MAPTAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL2213275 | 0.86 | MAPT (0.46) | FBP1MAPTAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL5408884 | 0.86 | AKR1C3 (0.50) | MAPTAKR1C3AKR1C2AKR1B10AKR1B1 | |
| SCHEMBL2327051 | 0.85 | KMT2A (0.47) | MAPTAKR1C3AKR1C2AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246808-B1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | BAYER SCHERING PHARMA AG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1246808-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
| WO-2001051473-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | FBP1 669/4885POLB 3310/4885MAPT 1799/4885 |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | FBP1 1026/4885POLB 3017/4885MAPT 829/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | FBP1 1026/4885POLB 3017/4885MAPT 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.